Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Regimen for Asymptomatic Tuberculosis (SWIFT)
NCT06153069Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of rifapentine, moxifloxacin in Tuberculosis (TB), sponsored by Huashan Hospital. Started Nov 2025; status: recruiting.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06153069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153069.